Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
What the film says
CAR T cells have cured some blood cancers. But they must be built from each patient's own blood, over weeks, and a relapsed patient may not have weeks.
The idea: build the cells in advance, from umbilical cord blood, so they wait in the freezer.
Natural killer cells from donated cord blood are given a receptor for CD70, a protein on many leukemias, lymphomas, and myelomas but few healthy cells. They also carry a gene for interleukin-15, a survival signal, so they persist. In myeloma models, they kept working after the usual target, BCMA, disappeared.
MD Anderson, with David Marin, gives one dose after chemotherapy makes room, to patients from age twelve whose cancer carries CD70. Safety first. Public record; not medical advice.
Sources behind this film
Liu E. N Engl J Med, 2020
Autologous CAR T takes weeks; off-the-shelf cord-blood NK cells
Autologous CAR T takes weeks; off-the-shelf cord-blood NK cells; Receptor for CD70, expressed on many hematologic cancers and few healthy cells; IL-15 gene for persistence; Single dose after lymphodepletion; ages 12–80; David Marin
Lin P. Blood Cancer Discov, 2026
Receptor for CD70, expressed on many hematologic cancers and few healthy cells; IL-15 gene for persistence; Kept working after BCMA loss in myeloma models
The drug
Primary Objective: To determine the safety, efficacy and optimal cell dose of CAR.70/IL15-transduced CB-NK cells in patients with relapsed/refractory hematological malignances. The efficacy and optimal dose will be identified for individual diseases. Secondary Objectives: * To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells in the recipient. * To conduct comprehensive immune reconstitution studies.
The study
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.